Lusaris Therapeutics
Morrisville, US · Founded 2021 · Delaware corporation
Founders & leadership
RF
Ramin Farzaneh-FarNamed on SEC filing
AL
Andrew LevinNamed on SEC filing
CR
Catherine RiesenNamed on SEC filing
DG
Daniel GrauNamed on SEC filing
EM
Edward MonaghanNamed on SEC filing
NB
Neil BuckleyNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$60.2M disclosed across 1 round · 2022
▶$60.2MraisedDec 2022 · 9 investors · PharmaceuticalsRule 506(b)
▶$60.2MraisedDec 2022 · 9 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Ramin Farzaneh-FarExecutive Officer
- Andrew LevinExecutive Officer, Director
- Catherine RiesenExecutive Officer
- Daniel GrauDirector
- Edward MonaghanExecutive Officer, Director, Promoter
- Neil BuckleyExecutive Officer
- Offering amount
- $60.2M
- Amount sold
- $60.2M
- First sale
- Oct 2022
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has Lusaris Therapeutics raised?
- Lusaris Therapeutics has disclosed $60.2M raised across 1 round.
- Where is Lusaris Therapeutics headquartered?
- Lusaris Therapeutics is headquartered in Morrisville, US.